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Abstract
Background: RNA polymerase (pol) III transcription is specifically elevated in a variety of cancers
and is a target of regulation by a variety of tumor suppressors and oncogenes. Accurate initiation
by RNA pol III is dependent on TFIIIB. In higher eukaryotes, two forms of TFIIIB have been
characterized. TFIIIB required for proper initiation from gene internal RNA pol III promoters is
comprised of TBP, Bdp1, and Brf1. Proper initiation from gene external RNA pol III promoters
requires TBP, Bdp1, and Brf2. We hypothesized that deregulation of RNA polymerase III
transcription in cancer may be a consequence of altered TFIIIB expression
Results: Here, we report: (1) the TFIIIB subunits Brf1 and Brf2 are differentially expressed in a
variety of cancer cell lines: (2) the Brf1 and Brf2 promoters differ in activity in cancer cell lines, and
(3) VAI transcription is universally elevated, as compared to U6, in breast, prostate and cervical
cancer cells.
Conclusion: Deregulation of TFIIIB-mediated transcription may be an important step in tumor
development. We demonstrate that Brf1 and Brf2 mRNA are differentially expressed in a variety
of cancer cells and that the Brf2 promoter is more active than the Brf1 promoter in all cell lines
tested. We also demonstrate, that Brf1-dependent VAI transcription was significantly higher than
the Brf2-dependent U6 snRNA transcription in all cancer cell lines tested. The data presented
suggest that Brf2 protein expression levels correlate with U6 promoter activity in the breast,
cervical and prostate cell lines tested. Interestingly, the Brf1 protein levels did not vary considerably
in HeLa, MCF-7 and DU-145 cells, yet Brf1 mRNA expression varied considerably in breast,
prostate and cervical cancer cell lines tested. Thus, Brf1 promoter activity and Brf1 protein
expression levels did not correlate well with Brf1-dependent transcription levels. Taken together,
we reason that deregulation of Brf1 and Brf2 expression could be a key mechanism responsible for
the observed deregulation of RNA pol III transcription in cancer cells.
Background
RNA polymerase III (RNA pol III) is the largest of the
eukaryotic DNA dependent RNA polymerases and tran-
scribes many of the genes involved in mRNA processing
(U6 snRNA) and protein translation (tRNA), thereby reg-
ulating the growth rate of a cell [1]. RNA pol III activity
has been demonstrated to be deregulated in a variety of
cancers, irrespective of tissue type (reviewed in [2-4]). Like
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all eukaryotic RNA polymerases, RNA pol III cannot rec-
ognize target promoter elements directly. Proper initia-
tion by RNA pol III requires the transcription factor TFIIIB
[1,5]. In higher eukaryotes, two forms of TFIIIB have been
identified thus far [6-8]. The form of TFIIIB required for
proper initiation from gene internal RNA pol III promot-
ers is comprised of TBP, Bdp1, and Brf1 [9,10]. Proper ini-
tiation from gene external RNA pol III promoters requires
TBP, Bdp1, and Brf2 [6-8].
TFIIIB is a molecular target of regulation by a wide variety
of tumor suppressors, including p53 [11-15], ARF [16],
PTEN [17], RB [18,19], and the RB-related pocket proteins
[20], as well as the oncogene c-myc [18,21] and the
mitogen-activated protein kinase ERK [22]. RNA pol III
and TFIIIB activity have also been demonstrated to be neg-
atively regulated by other proteins, such as Maf1 [23-26].
Maf1 is a common component of at least three signaling
pathways leading to repression of RNA pol III transcrip-
tion: the DNA damage signaling pathway, the secretory
defect signaling pathway, and the target of rapamycin
(TOR) signaling pathway (reviewed in [27,28]). More
recently, RNA pol III transcription has also been demon-
strated to be negatively regulated by the chemopreventa-
tive agent EGCG [29].
Taken together, these data suggest that deregulation of
TFIIIB-mediated transcription may be an important step
in tumor development. Thus, we hypothesized that the
observed specific elevation of RNA pol III transcription
products in cancer (reviewed in [2,4,30]) may be a result
of alterations in expression of the RNA pol III initiation
factor TFIIIB. Here, we report that the TFIIIB subunits Brf1
and Brf2 are differentially expressed in a variety of cancer
cell lines. We further demonstrate that the Brf1 and Brf2
promoters differ in activity in cancer cell lines, and VAI
transcription is universally elevated, as compared to U6
snRNA transcription, in breast, prostate and cancer cell
lines.
Results and Discussion
The TFIIIB subunits Brf1 and Brf2 are differentially 
expressed in cancer cell lines
Accurate initiation of transcription by RNA pol III requires
TFIIIB. Two of the TFIIIB subunits, Brf1 and Brf2, are struc-
turally related and are required for accurate transcription
by RNA pol III [1,7]. Brf1 is required for transcription
from gene internal promoters (tRNA), whereas Brf2 is
required for transcription from gene external RNA pol III
promoters (U6 snRNA). Hence, we sought to determine if
Brf1 and Brf2 expression is elevated in a variety of cancer
cell lines, contributing to the previously observed increase
of RNA pol III transcripts in cancer. We obtained a variety
of cervical, colorectal, breast, and prostate cancer cell lines
from the ATCC, isolated total RNA from asynchronous
cells, and by RT-PCR determined the expression levels of
Brf1 and Brf2 using gene specific primers (Table 1). Prim-
ers for β-actin (Table 1) were used as a control, Figure 1A.
Strikingly, the TFIIIB subunits Brf1 and Brf2 are differen-
tially expressed in breast, cervical and prostate cancer cell
lines (Figure 1B and 1C). We then speculated that the
observed differences in Brf1 and Brf2 expression is a con-
sequence of alterations in mRNA stability or may be a
result of differential activity of the Brf1 and Brf2 promot-
ers.
The Brf1 and Brf2 promoters differ in activity in breast, 
cervical and prostate cancer cell lines
To determine if the observed differences in Brf1 and Brf2
expression is a result of differences in transcription initia-
tion, we set out to directly compare the activities of the
Brf1 and Brf2 promoters. We have previously cloned the
human Brf2 promoter [29], and using a similar strategy
we cloned the human Brf1 promoter. Using
Gene2Promoter software of the Genomatix Suite, we
identified a putative promoter for Brf1, Figure 2A. We sub-
sequently amplified this putative promoter by PCR and
sub-cloned it into a promoterless pGL3-Basic vector, gen-
erating Brf1-pGL3. As expected, Brf1-pGL3 was able to
drive luciferase expression in a DNA concentration-
The TFIIIB subunits Brf1 and Brf2 are differentially expressed  in cancer cell lines Figure 1
The TFIIIB subunits Brf1 and Brf2 are differentially 
expressed in cancer cell lines. Total RNA was isolated 
from asynchronous growing Caski, HeLa, RKO, SIHA, Du 
145, ZR75-1, MCF-7, MDA-MB-453, MDA-MB-231, and 
MDA-MB-468 cells. After first strand cDNA synthesis, 
diluted cDNA was used in PCR using the primers depicted in 
Table 1. The mRNA expression of (A) β-actin, (B) Brf1, and 
(C) Brf2 are shown. The expected sizes of the PCR products 
of the different TFIIIB subunits are depicted.BMC Molecular Biology 2008, 9:74 http://www.biomedcentral.com/1471-2199/9/74
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dependent manner in all three cell lines tested: HeLa,
DU145 and MCF-7 (Figure 2). These cell lines were
selected since they all differentially expressed Brf1 and
Brf2. HeLa cells expressed higher levels of Brf2 than Brf1,
Figure 1. MCF-7 cells expressed higher levels of Brf1, as
compared to Brf2, Figure 1. The DU145 cell line expressed
only slightly higher levels of Brf1, as compared to Brf2
(Figure 1). Strikingly, in all three cell lines tested, the Brf2
promoter activity was significantly higher than the Brf1
promoter, Figure 2B–D, irrespective of Brf1 and Brf2
mRNA expression levels previously determined (Figure
1).
We cannot currently rule out the possibility that the
observed lower Brf1 promoter activity is a consequence of
enhancer sequences missing in the Brf1pGL3 construct
used in these studies. However, analysis of the Brf1 pro-
moter reveals several cis-acting elements which may nega-
tively regulate expression of Brf1. The Brf1 promoter
contains several binding sites for Krüppel-like zinc finger
Table 1: Primers used for semiquantitative RT-PCR analyses
Gene Forward Primer Reverse Primer
β-actin 5'-tagcggggttcacccacactgtgccccatcta-3' 5'-ctagaagcatttgcggtggaccgatggaggg-3'
Brf1 5'ggcattgatgacctggagat-3' 5'accagaggcctcaacctttt-3'
Brf2 5'cagaagtggagacccgagag-3' 5' cagggagggttagggacact-3'
The Brf1 and Brf2 promoters differ in activity in breast, cervical and prostate cancer cell lines Figure 2
The Brf1 and Brf2 promoters differ in activity in breast, cervical and prostate cancer cell lines. (A) Schematic rep-
resentation of the Brf1 promoter identified. The empty pGL3 vector (300 ng), as well as increasing concentrations of Brf1-
pGL3 (100 ng, 200 ng, 300 ng) and Brf2-pGL3 (100 ng, 200 ng, 300 ng) were transiently transfected into asynchronous (A) 
HeLa, (B) DU145, and (C) MCF-7 cells. All luciferase assay results are expressed as relative light units (RLU): the average of the 
Photinus pyralis firefly activity observed divided by the average of the activity recorded from the Renilla luciferase vector. 
Experiments were done in triplicate, repeated three times, and representative experiments are depicted.BMC Molecular Biology 2008, 9:74 http://www.biomedcentral.com/1471-2199/9/74
Page 4 of 8
(page number not for citation purposes)
transcription factors similar to Sp1, classified into struc-
tural subfamilies derived from variant sequences within
their N-terminal domains and termed KLF (Krüppel-like
factor) [31]. The Brf1 promoter has three binding sites for
the tumor suppressor ZF9, also known as KLF6 [32],
which could negatively regulate expression from the Brf1
promoter. Also, the Brf1 promoter contains multiple KLF3
binding sites, previously identified as a CtBp-mediated
repressor protein [31]. In addition, two ZF5 cis-regulatory
elements also are found within the Brf1 promoter. ZF5 is
a ubiquitous Kruppel-like zinc protein originally identi-
fied as a negative regulator of the c-myc promoter [33].
Taken together, these observations suggest that negative
regulation of the Brf1 promoter may account for the con-
sistently lower levels of Brf1 promoter activity as com-
pared to Brf2 in all cell lines tested (Figure 2).
The Brf1 promoter also contains binding sites for tran-
scription factors which could positively regulate Brf1
expression. For example, the Brf1 promoter contains a
Myc/Max binding site. Sansom et al, demonstrated using
a double mutant for Myc that Brf1 was no longer tran-
scriptionally upregulated in the absence of functional Myc
[34]. However, it is unclear if regulation of Brf1 expression
by Myc is a direct or indirect effect [34]. The Brf1 promoter
also contains several binding sites for nuclear respiratory
factor 1(NRF1), which has been implicated in the upregu-
lation of genes involved in fundamental cellular activities
[35] and mitochondrial respiratory function [36]. Addi-
tionally, the Brf1 promoter contains a binding site for
Zic2, a transcriptional activator that plays a role in mam-
malian forebrain development [37]. The Brf1 promoter
also contains an immediate early growth response (EGR1)
binding site. EGR1 is required for programmed cell death
or apoptosis in both normal and tumor cells, but has also
been determined to stimulate the differentiation of sev-
eral cell types [38]. Hence, positive and negative regula-
tion of Brf1 expression may be a key event in regulating
the growth rate of a cell.
VAI transcription is universally higher than U6 snRNA 
transcription, in breast, prostate and cancer cell lines
The interesting observations that the Brf2 promoter is
more active than the Brf1 promoter in all cell lines tested
and that Brf1 and Brf2 mRNA are differentially expressed
in cervical, breast and prostate cancer cell lines led us to
speculate what effects these observations have on protein
expression levels of Brf1 and Brf2. Thus, we determined
the endogenous protein levels of Brf1 and Brf2 in HeLa,
MCF-7 and DU145 cells (Figure 3A). The Brf1 protein lev-
els did not vary considerably in the breast, cervical and
prostate lines tested (Figure 3A). However, the Brf2 pro-
tein expression levels differed significantly between the
cervical, breast and prostate cancer cell lines tested, as
compared to β-actin (Figure 3A).
We then speculated what effect Brf1 and Brf2 protein con-
centrations had on VAI and U6 snRNA transcription levels
in breast, prostate and cervical cancer cell lines. To address
this issue we transiently transfected asynchronous HeLa,
MCF-7, and DU145 cells with increasing concentrations
of the U6 snRNA (pGL3-U6) and the VAI (pGL3-VAI) pro-
moters [26]. In all three cell lines tested, VAI transcription
levels were higher than U6 snRNA, Figure 3B–D. This
result was surprising as we have previously observed that
Brf1 and Brf2 are differentially expressed (Figure 1) and
the U6 specific TFIIIB subunit Brf2 promoter activity was
significantly higher than Brf1 promoter activity in all three
cell lines tested (Figure 2). Although the Brf1 protein lev-
els did not vary much in HeLa, MCF-7 and DU-145 cells,
VAI transcription levels in these cancer cell lines varied
considerably. VAI transcription was approximately five
fold higher in HeLa cells (Figure 3B), as compared to DU-
145 (Figure 3C) and MCF-7 cells (Figure 3D). One possi-
ble reason that the observed VAI transcription levels did
not correlate well with Brf1 protein levels is that cancer
VAI transcription is higher than U6 snRNA transcription in  HeLa, DU145, and MCF-7 cells Figure 3
VAI transcription is higher than U6 snRNA transcrip-
tion in HeLa, DU145, and MCF-7 cells. The empty pGL3 
vector (300 ng), as well as increasing concentrations of 
pGL3-U6 (100 ng, 200 ng, 300 ng) and pGL3-VAI (100 ng, 
200 ng, 300 ng) were transiently transfected into asynchro-
nous (A) HeLa, (B) DU145, and (C) MCF-7 cells. All luci-
ferase assay results are expressed as relative light units 
(RLU): the average of the Photinus pyralis firefly activity 
observed divided by the average of the activity recorded 
from the Renilla luciferase vector. Experiments were done in 
triplicate, repeated three times, and representative experi-
ments are depicted. (D) Western blot analysis of Brf1 and 
Brf2 protein levels in HeLa, MCF-7 and DU145 cells. 25 μg of 
nuclear extract was immunoblotted with anti-Brf1 (CS1043) 
and anti-Brf2 (CS1228) antibodies. As loading control, mem-
brane was also immunoblotted with an anti-actin antibody, 
bottom panel. Arrows depict migration of actin, Brf1 and 
Brf2.BMC Molecular Biology 2008, 9:74 http://www.biomedcentral.com/1471-2199/9/74
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cells may already express Brf1 levels far above limiting
concentrations for RNA pol III transcription. Interestingly,
there is a correlation between Brf2 protein levels (Figure
3A) and the activity of the U6 promoter in HeLa (Figure
3B), DU-145 (Figure 3C) and MCF-7 (Figure 3D) cells.
We speculate the differences in Brf1 and Brf2 mRNA
expression and promoter activities, as well as the observed
differences in TFIIIB-mediated RNA pol III transcription is
a consequence of differences in Brf1 and Brf2 mRNA sta-
bility. Differences in Brf1 and Brf2 mRNA stability may, in
part, account for the differences in the endogenous pro-
tein levels of Brf1 and Brf2 observed in Figure 3A, as com-
pared to mRNA expression levels in Figure 1B–C.
Modulation of mRNA stability provides a rapid mecha-
nism for regulating protein levels, independent of tran-
scription initiation. A major mechanism controlling the
rate of mRNA turnover is the regulation of destabilizing
cis-regulatory elements within a given transcript [39].
mRNA destabilizing cis-regulatory elements have been
localized as coding region determinant (CRD) sequences
[40-43], or as the more common AU-rich elements (ARE)
in the 3'UTR [44] of a transcript. These AU-rich elements
are heterogenous in terms of length, AU-content and
3'UTR location. However, AREs may be classified based
on sequence criteria [42,45,46]. Class I AREs contain mul-
tiple canonical AUUUA sites within the 3' UTR and Class
II contains multiple AUUUA sites which may overlap
resulting in an AUUUAUUUA sequence. The Class III
AREs have U-rich regions in the 3'UTRs, without a canon-
ical AUUUA site.
Using the ElDorado software of the Genomatix suite we
identified 3'UTRs for Brf1 and Brf2 (data not shown). The
3'UTRs of Brf1 and Brf2 were AU-rich, 25% and 52%
respectively, but do not appear to contain classical Class I
or Class II AU-rich elements. However, it remains to be
experimentally determined if the significant AU-content
of the 3'UTR of Brf2 plays a role in regulating Brf2 mRNA
turnover.
We cannot currently rule out the possibility that Brf1 and
Brf2 mRNA stability is regulated by coding region deter-
minant elements as previously described for c-fos [41], c-
myc [40,43], and MnSOD [47]. Using Align X (Invitro-
gen), we aligned the coding sequences of Brf1 (ntds
1666–1858) and Brf2 (ntds 1257–1456) with a c-myc
nucleotide sequence corresponding to a 60 amino acid
region (372–412) previously defined as a coding region
determinant [40,43] (Figure 4). Strikingly, within the cod-
ing regions for the c-terminus of Brf1 and Brf2, there was
a high degree of sequence identity with the coding deter-
minant region of c-myc: Brf1 was 50.5% identical and
Brf2 50.1%. We will experimentally determine whether
these regions indeed influence Brf1 and Brf2 mRNA sta-
bility, ultimately providing an additional mechanism for
regulation of basal RNA pol III transcription factors.
Conclusion
We have demonstrated that the TFIIIB subunits Brf1 and
Brf2 are differentially expressed at the mRNA level in a
variety of cancer cells (Figure 1). We also show that the
Brf2 promoter is more active than the Brf1 promoter in
the breast, prostate and cervical cell lines tested (Figure
2B–D). Brf1-dependent VAI transcription was signifi-
cantly higher than the Brf2-dependent U6 snRNA tran-
scription in HeLa, DU-145 and MCF-7 cell lines (Figure
3B–D). Surprisingly, the Brf1 protein levels did not vary
considerably in HeLa, MCF-7 and DU-145 cells (Figure
3A), yet Brf1 mRNA expression varied considerably in the
cancer cell lines tested (Figure 1B). Thus, Brf1 promoter
activity (Figure 2B–D) and Brf1 protein expression (Figure
3A) levels did not correlate well with Brf1-dependent tran-
scription levels (Figure 3B–D).
Brf1 and Brf2 have a high sequence similarity to the codon  determinant region of c-myc Figure 4
Brf1 and Brf2 have a high sequence similarity to the 
codon determinant region of c-myc. (A) Schematic rep-
resentation of Brf1, Brf2 and c-myc. Structural features are 
indicated. Location of nucleotide sequences aligned (red text) 
in lower panel are indicated by red brackets. (B) Sequence 
alignment of the codon determinant region of c-myc, Brf1 
and Brf2. Identical amino acids in all three sequences are 
depicted in yellow. Sequences identical in two of the three 
sequences are highlighted in blue. Consensus sequence is 
indicated.BMC Molecular Biology 2008, 9:74 http://www.biomedcentral.com/1471-2199/9/74
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Interestingly, we have observed that Brf2 protein levels
(Figure 3A) may correlate with U6 snRNA transcription
rates in the breast, cervical and prostate cancer cell lines
tested (Figure 3B–D). Hence, we speculate that since Brf2
has been shown to be amplified in breast cancers and has
been proposed to be a candidate oncogene [48,49], strict
regulation of Brf2 expression could be critical in prevent-
ing the oncogenic phenotype. Also, Brf1 expression has
been demonstrated to be induced in cervical cells infected
with papilloma virus [50] and cardiomyocytes undergo-
ing hypertrophy [51,52]. In addition, Brf1 has been
shown to be a direct target of activation by c-myc and ERK
[21,22], both known to play a key role in cancer patho-
genesis. Taken together, we reason that deregulation of
Brf1 and Brf2 expression could be a key mechanism
responsible for the observed deregulation of RNA pol III
transcription in cancer cells.
Methods
Cell Lines and Culture
C33A, Caski, HeLa, RKO, SiHa, DU145, ZR75-1, MCF-7,
MDA-MB-453, MDA-MB-231, and MDA-MB-468 cells
were obtained from the American Type Culture Collection
(Rockville, MD). Cells were cultured in DMEM or RPMI
supplemented with FCS (5% v/v), nonessential amino
acids (100 mM), L-glutamine (5 mM), streptomycin (100
μg/ml), and penicillin (100 units/ml; all from BioWhit-
taker, Walkersville, MD). Cells were grown at 37°C in a
humidified atmosphere of 95% air and 5% CO2.
Total RNA Isolation
Total RNA was extracted from the subconfluent 100 mm
dishes of the cancer cell lines indicated using TRIzol Rea-
gent (Life Technologies, Inc.), according to the manufac-
turer's protocol. The RNA was DNase (Ambion) treated
and ethanol precipitated prior to cDNA synthesis. Isolated
RNA was electrophoresed through 1.0% agarose-formal-
dehyde gels to verify the quality of the RNA, and RNA con-
centrations were determined from absorbance
measurements at 260 and 280 nm.
Semiquantitative RT-PCR Analysis
Aliquots of total cellular RNA (1.0 μg) were subjected to
first-strand cDNA synthesis using Superscript II reverse
transcriptase (Life Technologies, Inc.), and the cDNA was
diluted five times with water and 1μl of the diluted cDNA
was used for each PCR reaction. PCR amplifications were
performed using a Techgene TC312 DNA thermal cycler.
The PCR primer sets used in this study are shown in Table
1. The PCR reaction conditions were individually opti-
mized for each gene product tested in this study. For each
gene product, the cycle number was adjusted so that the
reactions fell within the linear range of product amplifica-
tion. The β-actin gene was used as a loading control. PCR
products were analyzed by electrophoresis through 1.2%
agarose gels containing 0.1 mg/ml of ethidium bromide,
and the gels were photographed using a UVP BioDocit sys-
tem.
Cloning of the human Brf1 promoter
Gene2Promoter analysis software program of Genomatix
Suite http://www.genomatix.de was utilized to identify a
putative promoter for human Brf1. Putative transcription
factor sites within the human Brf1 promoter were identi-
fied using MatInspector [53] of the Genomatix Suite. PCR
primers flanking the Brf1 promoter sequence were
designed with KpnI and BglII restriction sites and used to
PCR amplify the promoter sequence from human
genomic DNA and cloned into the KpnI and BglII sites of
the promoterless pGL3 Basic vector (Promega).
Luciferase Assays
Increasing concentrations of Brf1-pGL3 and Brf2-pGL3
[29] were transiently transfected using TransIT-LT1
(Mirus), as per the manufacturer's protocol in HeLa, MCF-
7 and DU145 cells. pGL3-VAI and pGL3-U6 luciferase
assays were performed as previously described [26]. In
brief, the human U6 and VAI promoters were cloned into
the promoterless pGL3 vector, generating pGL3-VAI and
pGL3-U6. The dual-luciferase reporter assay system
(Promega) was used to monitor luciferase activity in
HeLa, DU 145 and MCF-7 cells as per the manufacturer's
recommendations, using a Sirius single tube luminometer
(Berthold). A Renilla luciferase vector (Promega) was co-
transfected in all transfections to monitor transfection
efficiency. Luciferase experiments were performed in trip-
licate or quadruplicate, repeated three independent times,
and the data presented are representative experiments. All
luciferase results are reported as relative light units (RLU):
the average of the Photinus pyralis firefly activity observed
divided by the average of the activity recorded from
Renilla luciferase vector and graphed using
GraphpadPrism3.03 (San Diego California USA).
Western Blots
HeLa, MCF-7 and DU145 cells were harvested and nuclear
extract was prepared as previously described [7]. Nuclear
extract (25 μg) was separated on 10% SDS-PAGE gels,
semi dry transferred to nitrocellulose, blocked 1 hour
room temperature using nonfat milk in Phosphate Buff-
ered Saline (PBS), pH 7.5. The blot(s) were incubated in
primary antibodies: anti-actin (Santa Cruz), anti-Brf1
(CS407) or anti-Brf2 (CS1228) polyclonal antibodies,
overnight at 4 degrees. The blot(s) were washed in 1× PBS
and then incubated in secondary antibody at room tem-
perature, then developed using ECF (for anti-rabbit-AP)
or TMB substrate (Promega) (for anti-goat-HRP, Amer-
sham) and photodocumented using a BioDocit system
(UVP).BMC Molecular Biology 2008, 9:74 http://www.biomedcentral.com/1471-2199/9/74
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